MDM2 and glioblastoma: These results along with the demonstration of pleiotropic activities of nutlin-3a by inducing cell cycle arrest and senescence, and apoptosis in glioblastoma cells make MDM2 inhibitors particularly attractive for the treatment of glioblastoma patients.